SMMT — Summit Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $17.31bn
- $16.90bn
- 36
- 20
- 89
- 46
Annual income statement for Summit Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.86 | 1.81 | 0.705 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 54.1 | 88 | 72.8 | 610 | 226 |
| Operating Profit | -53.2 | -86.2 | -72.1 | -610 | -226 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -52.9 | -88.6 | -78.8 | -615 | -221 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -52.7 | -88.6 | -78.8 | -615 | -221 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -52.7 | -88.6 | -78.8 | -615 | -221 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -52.7 | -88.6 | -78.8 | -615 | -221 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.75 | -0.961 | -0.364 | -0.152 | -0.287 |